Home » Stocks » NURO

NeuroMetrix, Inc. (NURO)

Stock Price: $2.98 USD 0.06 (2.05%)
Updated May 10, 2021 4:00 PM EDT - Market closed
After-hours: $2.99 +0.01 (0.34%) May 10, 7:00 PM
Market Cap 11.30M
Revenue (ttm) 7.36M
Net Income (ttm) -1.49M
Shares Out 3.80M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $2.98
Previous Close $2.92
Change ($) 0.06
Change (%) 2.05%
Day's Open 2.99
Day's Range 2.92 - 3.00
Day's Volume 85,748
52-Week Range 1.39 - 5.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WOBURN, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in propr...

2 weeks ago - GlobeNewsWire

WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on Apr...

3 weeks ago - GlobeNewsWire

NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q4 2020 Results - Earnings Call Transcript

3 months ago - Seeking Alpha

WOBURN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focuse...

3 months ago - GlobeNewsWire

WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the...

3 months ago - GlobeNewsWire

NeuroMetrix (NASDAQ: NURO) is currently up 45.17% to a price of $3.04. The stock's volume is currently 62.04 million, which is roughly 32668.92% of its recent 30-day volume average of 189.91 thousand.

5 months ago - Benzinga

NeuroMetrix (NURO) stock is on the rise Tuesday with heavy trading despite a lack of news concerning the medical device company. The post NURO Stock: 10 Things for Potential Investors to Know About Neur...

5 months ago - InvestorPlace

NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading deve...

6 months ago - GlobeNewsWire

WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on Octob...

6 months ago - GlobeNewsWire

Who Will Win The Lucrative Autonomous Vehicles (Robotaxis) Race?

Other stocks mentioned: APTV, BMWYY, DMLRY, F, FCAU, GM, HYMTF ...
7 months ago - Seeking Alpha

WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store.

7 months ago - GlobeNewsWire

WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269...

7 months ago - GlobeNewsWire

WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held Septe...

8 months ago - GlobeNewsWire

WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of di...

8 months ago - GlobeNewsWire

WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of t...

8 months ago - GlobeNewsWire

WOBURN, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technology addres...

9 months ago - GlobeNewsWire

NeuroMetrix's (NURO) CEO Shai Gozani on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

WOBURN, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading develop...

9 months ago - GlobeNewsWire

WOBURN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Th...

9 months ago - GlobeNewsWire

WOBURN, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test f...

10 months ago - GlobeNewsWire

WOBURN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropat...

10 months ago - GlobeNewsWire

WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direc...

11 months ago - GlobeNewsWire

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

WOBURN, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH-funded, randomized, pragmatic clinica...

1 year ago - GlobeNewsWire

WOBURN, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline.

1 year ago - GlobeNewsWire

WOBURN, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a point-of-care test...

1 year ago - GlobeNewsWire

NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2019 Results Conference Call January 27, 2020 8:00 AM ET

1 year ago - Seeking Alpha

Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on November 19, 2019 Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on ...

1 year ago - GlobeNewsWire

NeuroMetrix's (NURO) CEO Shai Gozani on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

WOBURN, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2019.

1 year ago - GlobeNewsWire

WOBURN, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company that develops and commercializes products for the chronic pain and diabetes markets, today...

1 year ago - GlobeNewsWire

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About NURO

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to ... [Read more...]

Industry
Medical Instruments & Supplies
Founded
1996
CEO
Shai Gozani
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
NURO
Full Company Profile

Financial Performance

In 2020, NeuroMetrix's revenue was $7.38 million, a decrease of -20.43% compared to the previous year's $9.27 million. Losses were -$2.09 million, -44.55% less than in 2019.

Financial Statements